Acquired (drug-induced) long QT syndrome

Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention

Volumn , Issue , 2008, Pages 705-718

  Litwin, Jeffrey S ^a   Kleiman, Robert B ^a   Gussak, Ihor ^b,c  

^a EResearch Technology Inc   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856233940     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-854-8_50     Document Type: Chapter

References (31)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-1022.
2. Legebrve RA, Van Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effect of astemizole. Br J Clin Pharmacol 1997;43:319-322.
3. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-341.
4. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96(6):1698-1703.
5. Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, Lopez H. Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 1993;72:26B-32B.
6. Gussak I, Litwin J, Kleiman R, Grisanti S, Morganroth J. Drug-induced cardiac toxicity: Emphasizing the role of electrocardiography in clinical research and drug development. J Electrocardiol 2004;37(1):19-24.
7. Rautaharju PM. A farewell to QT dispersion. Are the alternatives any better? J Electrocardiol 2005;38(1):7-9.
8. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98(18):1928-1936.
9. Zabel M, Malik M, Hnatkova K, Papademetriou V, Pittaras A, Fletcher RD, Franz MR. Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans. Circulation 2002;105(9):1066-1070.
10. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92(10):2929-2934.
11. Nearing BL, Verrier RL. Progressive increases in complexity of T-wave oscillations herald ischemiainduced ventricular fibrillation. Circ Res 2002;91(8):727-732.
12. Nearing BD, Verrier RL. Modified moving average analysis of T-wave alternans to predict ventricular fibrillation with high accuracy. J Appl Physiol 2002;92(2):541-549.
13. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001;50:224-231.
14. Roden DM, Spooner PM. Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 1999;10:1664-1683.
15. Nattel S, Li DS. Ionic remodeling in the heart-pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000;87:440-447.
16. Roden DM, Spooner PM. Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 1999;10:1664-1683.
17. Abbott GW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
18. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen La Pointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114(2):135-141.
19. Shah RR. Drug-induced prolongation of the QT interval: Why the regulatory concern? Fundam Clin Pharmacol 2002;16(2):119-124.
20. Shah RR. Interpretation of clinical ECG data: Understanding the risk from non-antiarrhythmic drugs. In: Morganroth J, Gussak I, Eds. Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Totowa, NJ: Humana Press, 2004:259-301.
21. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984;107(3):425-430.
22. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72(4):44A-50A.
23. Moss AJ, Schwartz PJ. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 1982;51(3):85-90.
24. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105(16):1943-1948.
25. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5(2):515-530.
26. Committee for Proprietary Medicinal Products (CPMP). Points to consider: The assessment of the potential for QT interval prolongation by noncardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. 17 December 1997.
27. Health Canada: Draft Guidance "Assessment of the QT prolongation potential of non-antiarrhythmic drugs", March 15, 2001. Available from http://www.hc-sh.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html.
28. Food and Drug Administration and Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. 2002 Preliminary Concept paper, November 15. Available from http://www.fda.gov/cder/workshop.htm#upcoming.
29. Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). October 2005. http://www.fda.gov/cder/guidance/6922fnl.htm.
30. Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004;37(1):25-29.
31. Pratt CM, Ruberg S, Morganroth J, et al. Doseresponse relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472.